【與漢康讀懂腫瘤免疫新藥的抗癌革命】由漢康生技企劃製作

當全球 74% 仍停留在單功能抗體時，為何漢康生技選擇投入僅佔 1.6% 的三功能藥物開發？
在 PD-1 / PD-L1 已獲諾貝爾肯定後，為什麼仍有超過一半患者反應有限？
HCB301 如何同時啟動先天免疫與後天免疫，打破腫瘤微環境的防禦牆？
本集我們特別邀請到漢康生技研發副總曾琪鈴博士，深入解析 HCB30X 系列三功能融合蛋白的設計邏輯與商業戰略。從 CD47、PD-L1 到 TGF-β（Tgβ）微環境標靶，漢康生技如何以「海陸空三軍聯合作戰」概念，打造下一代免疫治療武器？

精彩內容：

• PD-1 突破後的限制： 為什麼免疫檢查點療法已改寫癌症治療史，卻仍有超過 70% 病人反應不佳？

• 三功能戰略意義： 為何將 A+B+C 整合成單一分子，比傳統聯合療法更具臨床效率與經濟優勢？

• 技術門檻與挑戰： 為什麼三功能融合蛋白在分子設計、穩定性與製程放大上極具難度？

• HCB301 的核心差異化： 它如何同時解除免疫抑制、活化巨噬細胞並啟動 T 細胞攻擊？

• 產品線定位策略： HCB30X 系列如何與 HCB101 差異化布局，避免內部競爭並擴大全球市場？

• 臨床關鍵訊號： 完成兩個劑量爬升階段，為何成為安全性驗證與國際授權談判的重要籌碼？

無論你是長期投資人、醫療專業人士，或關注全球生技趨勢的聽眾，都值得深入了解這 1.6% 背後的產業邏輯。

【About This Episode】
When 74% of global biologics remain single-function antibodies, why did HanchorBio choose to enter the 1.6% frontier of tri-functional drugs?
Even after the Nobel-recognized breakthrough of PD-1/PD-L1, why do over half of patients still show limited response?
How does HCB301 activate both innate and adaptive immunity to dismantle the tumor’s defensive microenvironment?
In this episode, Dr. Chi Ling Tseng breaks down the scientific logic and commercial strategy behind the HCB30X tri-functional fusion protein series developed by HanchorBio. By integrating CD47 targeting, PD-L1 blockade, and TGF-β modulation into a single molecule, HanchorBio aims to deliver a coordinated “multi-front immune assault” against cancer.

【Key Takeaways】
Limitations After PD-1 Breakthrough: Why do immune checkpoint inhibitors still leave a majority of patients without durable response?
Strategic Rationale for Tri-Functionality: How does integrating A+B+C into one molecule enhance both efficacy and cost-effectiveness compared to combination therapy?
Engineering Barriers: What makes tri-functional fusion proteins exceptionally challenging to design and manufacture?
Differentiation Strategy: How does HCB301 complement—rather than compete with—HCB101 within the pipeline?
Clinical Signals That Matter: Why is successful dose escalation a pivotal milestone for safety validation and global licensing leverage?

This episode explores not only a next-generation immunotherapy candidate, but also the strategic blueprint behind platform-driven biotech innovation.

漢康生技官網：https://www.hanchorbio.com/
漢康生技LinkedIn：https://reurl.cc/7b19y9

本節目旨在透過科學導讀與商業邏輯分享，幫助聽眾理解生技產業趨勢與漢康生技之核心價值。所有臨床數據均以公司正式發布之公告為準，內容不構成任何形式之投資建議。以上內容為創辦人基於產業經驗對產品潛力的評估，不代表公司對未來股價或獲利的保證。